Literature DB >> 23480180

CXCR3 axis in patients with primary biliary cirrhosis: a possible novel mechanism of the effect of ursodeoxycholic acid.

P Manousou1, G Kolios, I Drygiannakis, M Koulentaki, K Pyrovolaki, A Voumvouraki, G Notas, L Bourikas, H A Papadaki, E Kouroumalis.   

Abstract

The CXC chemokines, monokine induced by interferon (IFN)-gamma (MIG) (CXCL9), IFN-gamma-induced protein 10 (IP-10) (CXCL10) and IFN-inducible T cell alpha chemoattractant (I-TAC) (CXCL11), are known to attract CXCR3- (CXCR3A and CXCR3B) T lymphocytes. We investigated MIG, IP-10 and I-TAC mRNAs expression by semi-quantitative multiplex reverse transcription-polymerase chain reaction (RT-PCR) in liver biopsies obtained from patients with a first diagnosis of primary biliary cirrhosis [(PBC) = 20] compared to patients with normal liver biopsy [normal controls (NCs) = 20]. Chemokine production was assessed by enzyme-linked immunosorbent assay (ELISA) in serum. Measurements were repeated 6 months after ursodeoxycholic acid (UDCA) treatment in PBC patients. CXCR3A and CXCR3B mRNAs expression was examined in immunomagnetically sorted CD3(+) peripheral blood lymphocytes (PBL) pre- and post-treatment by RT-PCR. Flow cytometry was used to evaluate the expression of CXCR3(+) PBLs of NCs and PBC patients. A marked mRNA expression of MIG and IP-10 was found in PBC patients. I-TAC mRNA was not detected. In serum of PBC patients there was a significant increase of MIG and IP-10 compared to NCs. Interestingly, there was a significant reduction of these proteins in patients' serum after UDCA treatment. I-TAC was not statistically different between groups. CXCR3A mRNA expression was found in PBLs from PBC patients as well as in NCs. CXCR3B mRNA was expressed in four of 20 (19%) NCs and 20 of 20 PBC patients. Flow cytometry revealed a significantly lower CXCR3 expression in NCs (13·5%) than in PBC (37·2%), which was reduced (28·1%, P < 0·01) after UDCA administration. These data suggest a possible role for CXCR3-binding chemokines and their receptor in the aetiopathogenetic recruitment of lymphocytes in PBC and a new mechanism of action for UDCA.
© 2012 British Society for Immunology.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23480180      PMCID: PMC3719926          DOI: 10.1111/cei.12032

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  34 in total

1.  Promotion of leukocyte transendothelial cell migration by chemokines derived from human biliary epithelial cells in vitro.

Authors:  C M Morland; J Fear; G McNab; R Joplin; D H Adams
Journal:  Proc Assoc Am Physicians       Date:  1997-07

2.  Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis).

Authors:  J Ludwig; E R Dickson; G S McDonald
Journal:  Virchows Arch A Pathol Anat Histol       Date:  1978-08-22

3.  Chemokine and chemokine receptor interactions provide a mechanism for selective T cell recruitment to specific liver compartments within hepatitis C-infected liver.

Authors:  P L Shields; C M Morland; M Salmon; S Qin; S G Hubscher; D H Adams
Journal:  J Immunol       Date:  1999-12-01       Impact factor: 5.422

Review 4.  Mig and IP-10: CXC chemokines that target lymphocytes.

Authors:  J M Farber
Journal:  J Leukoc Biol       Date:  1997-03       Impact factor: 4.962

5.  Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes.

Authors:  M Loetscher; B Gerber; P Loetscher; S A Jones; L Piali; I Clark-Lewis; M Baggiolini; B Moser
Journal:  J Exp Med       Date:  1996-09-01       Impact factor: 14.307

Review 6.  Recruitment of lymphocytes to the human liver.

Authors:  Patricia F Lalor; Philip Shields; AllisterJ Grant; David H Adams
Journal:  Immunol Cell Biol       Date:  2002-02       Impact factor: 5.126

Review 7.  Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited.

Authors:  Gustav Paumgartner; Ulrich Beuers
Journal:  Hepatology       Date:  2002-09       Impact factor: 17.425

8.  Increased cell apoptosis in bone marrow trephine biopsies and immunomagnetically isolated myeloid progenitor cells in patients with chronic idiopathic neutropenia.

Authors:  V Koumaki; H A Papadaki; K Stefanaki; A Damianaki; C Gemetzi; P Katonis; G Vrentzos; G D Eliopoulos
Journal:  Ann Hematol       Date:  2003-08-02       Impact factor: 3.673

9.  An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4.

Authors:  Laura Lasagni; Michela Francalanci; Francesco Annunziato; Elena Lazzeri; Stefano Giannini; Lorenzo Cosmi; Costanza Sagrinati; Benedetta Mazzinghi; Claudio Orlando; Enrico Maggi; Fabio Marra; Sergio Romagnani; Mario Serio; Paola Romagnani
Journal:  J Exp Med       Date:  2003-06-02       Impact factor: 14.307

10.  CXCR3-dependent recruitment and CCR6-mediated positioning of Th-17 cells in the inflamed liver.

Authors:  Ye Htun Oo; Vanessa Banz; Dean Kavanagh; Evaggelia Liaskou; David R Withers; Elizabeth Humphreys; Gary M Reynolds; Laura Lee-Turner; Neena Kalia; Stefan G Hubscher; Paul Klenerman; Bertus Eksteen; David H Adams
Journal:  J Hepatol       Date:  2012-07-14       Impact factor: 25.083

View more
  11 in total

Review 1.  Primary biliary cirrhosis: From bench to bedside.

Authors:  Elias Kouroumalis; George Notas
Journal:  World J Gastrointest Pharmacol Ther       Date:  2015-08-06

Review 2.  Novel therapeutic targets in primary biliary cirrhosis.

Authors:  Jessica K Dyson; Gideon M Hirschfield; David H Adams; Ulrich Beuers; Derek A Mann; Keith D Lindor; David E J Jones
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-02-03       Impact factor: 46.802

Review 3.  Immune Cell Trafficking to the Liver.

Authors:  Sulemon Chaudhry; Jean Emond; Adam Griesemer
Journal:  Transplantation       Date:  2019-07       Impact factor: 4.939

Review 4.  Transitioning from Idiopathic to Explainable Autoimmune Hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2015-05-22       Impact factor: 3.199

5.  A dual farnesoid X receptor/soluble epoxide hydrolase modulator treats non-alcoholic steatohepatitis in mice.

Authors:  Md Abdul Hye Khan; Jurema Schmidt; Anna Stavniichuk; John D Imig; Daniel Merk
Journal:  Biochem Pharmacol       Date:  2019-05-23       Impact factor: 5.858

6.  The effects of ursodeoxycholic acid on sepsis-induced cholestasis management in an animal model.

Authors:  Randa H Ainosah; Magda M Hagras; Sameer E Alharthi; Omar I Saadah
Journal:  J Taibah Univ Med Sci       Date:  2020-06-27

Review 7.  Chemokine and chemokine receptors in autoimmunity: the case of primary biliary cholangitis.

Authors:  Jinjung Choi; Carlo Selmi; Patrick S C Leung; Thomas P Kenny; Tania Roskams; M Eric Gershwin
Journal:  Expert Rev Clin Immunol       Date:  2016-02-25       Impact factor: 4.473

8.  Functional and structural features of cholangiocytes in health and disease.

Authors:  Luca Maroni; Bai Haibo; Debolina Ray; Tianhao Zhou; Ying Wan; Fanyin Meng; Marco Marzioni; Gianfranco Alpini
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2015-07-01

9.  NI-0801, an anti-chemokine (C-X-C motif) ligand 10 antibody, in patients with primary biliary cholangitis and an incomplete response to ursodeoxycholic acid.

Authors:  Kathy L de Graaf; Geneviève Lapeyre; Florence Guilhot; Walter Ferlin; Stuart M Curbishley; Marco Carbone; Paul Richardson; Sulleman Moreea; C Anne McCune; Stephen D Ryder; Roger W Chapman; Annarosa Floreani; David E Jones; Cristina de Min; David H Adams; Pietro Invernizzi
Journal:  Hepatol Commun       Date:  2018-03-23

10.  Mesenchymal stem cells alleviate experimental autoimmune cholangitis through immunosuppression and cytoprotective function mediated by galectin-9.

Authors:  Junyu Fan; Xiaojun Tang; Qian Wang; Zhuoya Zhang; Shufang Wu; Wenchao Li; Shanshan Liu; Genhong Yao; Hongwei Chen; Lingyun Sun
Journal:  Stem Cell Res Ther       Date:  2018-09-17       Impact factor: 6.832

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.